Investigating how blood type and genetic factors contribute to heparin-induced thrombocytopenia
Official title: ABO and Immunogenetic Variation in the Pathogenesis of Heparin-Induced Thrombocytopenia
Funded at University of Arizona · NIH-10886615 · Data updated 2026-11-12
This study is looking at how some people might have a bad reaction to heparin, a common blood thinner, and aims to find out if certain genes or immune responses can help predict who might be at risk, so doctors can better protect patients before they start treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project start | July 1, 2022 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $529,885 |
| NIH project number | 5R01HL156993-03 |
| Project ID | NIH-10886615 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who are scheduled to receive heparin treatment and have specific ABO blood types or genetic markers.
✕Less likely to help
Patients who do not require heparin treatment or have no history of adverse reactions to heparin may not benefit from this research.
What this research studies
This research focuses on understanding heparin-induced thrombocytopenia (HIT), a serious immune reaction that can occur in patients receiving heparin, a common blood thinner. The study aims to identify genetic variations and immune responses that may predict who is at risk for developing HIT. By analyzing blood samples and genetic data, researchers hope to differentiate between harmful and harmless antibodies related to HIT. This could lead to the development of biomarkers that help clinicians identify patients at risk before they receive heparin treatment.
Why it matters
Potential benefit: If successful, this research could lead to safer heparin use by identifying patients at risk for HIT, potentially saving lives and reducing complications.
How similar studies have gone: Previous research has shown promise in identifying genetic factors related to HIT, but this study aims to explore novel approaches that have not been extensively tested.
Where this research is happening
-
University of Arizona
Tucson, United States Active
Researchers
- Principal investigator: Karnes, Jason Hansen — University of Arizona
- Study coordinator: Karnes, Jason Hansen
Related research
Other NIH-funded projects on the same topics.
-
New ideas to understand, diagnose, and treat heparin-induced thrombocytopenia
A Mayo Clinic led study will look at the different kinds of HIT antibodies to improve diagnosis and treatment for people with HIT.
-
Second-generation BLVRB inhibitors to help chemotherapy patients with low platelets
A new drug candidate is being developed to raise platelet counts in patients whose cancer treatment lowers them, reducing bleeding risk.
-
Immunobiology of vaccine-related clotting after adenovirus vaccines
This research asks how antibodies linked to a rare vaccine-related clotting condition (VITT) interact with specific blood proteins to cause clots after certain COVID-19 vaccines.
-
Understanding and diagnosing Heparin-Induced Thrombocytopenia (HIT)
A project to understand the immune factors behind HIT and develop faster, more accurate tests to help people who need heparin therapy.
-
Fetal and neonatal platelet allergy: understanding why some babies bleed
A study to understand why maternal antibodies cause serious bleeding in babies with FNAIT, using an animal model and human-relevant clues to improve future care for affected families.
-
Molecular mechanisms behind immune-related low platelets and clots in transfusion medicine
This grant supports a team of researchers to understand how immune factors cause low platelets and abnormal clots, with a focus on transfusion medicine and pediatric to adult patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.